Cargando…
Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients
Background: Pyruvate kinase deficiency (PKD) is the most frequent congenital enzymatic defect of glycolysis, and one of the most common causes of hereditary non spherocytic hemolytic anemia. Therapeutic interventions are limited, in part because of the incomplete understanding of the molecular mecha...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567077/ https://www.ncbi.nlm.nih.gov/pubmed/34744776 http://dx.doi.org/10.3389/fphys.2021.735543 |
_version_ | 1784594157689372672 |
---|---|
author | Roy, Micaela K. Cendali, Francesca Ooyama, Gabrielle Gamboni, Fabia Morton, Holmes D’Alessandro, Angelo |
author_facet | Roy, Micaela K. Cendali, Francesca Ooyama, Gabrielle Gamboni, Fabia Morton, Holmes D’Alessandro, Angelo |
author_sort | Roy, Micaela K. |
collection | PubMed |
description | Background: Pyruvate kinase deficiency (PKD) is the most frequent congenital enzymatic defect of glycolysis, and one of the most common causes of hereditary non spherocytic hemolytic anemia. Therapeutic interventions are limited, in part because of the incomplete understanding of the molecular mechanisms that compensate for the metabolic defect. Methods: Mass spectrometry-based metabolomics analyses were performed on red blood cells (RBCs) from healthy controls (n=10) and PKD patients (n=5). Results: In PKD patients, decreases in late glycolysis were accompanied by accumulation of pentose phosphate pathway (PPP) metabolites, as a function of oxidant stress to purines (increased breakdown and deamination). Markers of oxidant stress included increased levels of sulfur-containing compounds (methionine and taurine), polyamines (spermidine and spermine). Markers of hypoxia such as succinate, sphingosine 1-phosphate (S1P), and hypoxanthine were all elevated in PKD subjects. Membrane lipid oxidation and remodeling was observed in RBCs from PKD patients, as determined by increases in the levels of free (poly-/highly-unsaturated) fatty acids and acyl-carnitines. Conclusion: In conclusion, in the present study, we provide the first overview of RBC metabolism in patients with PKD. Though limited in scope, the study addresses the need for basic science to investigate pathologies targeting underrepresented minorities (Amish population in this study), with the ultimate goal to target treatments to health disparities. |
format | Online Article Text |
id | pubmed-8567077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85670772021-11-05 Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients Roy, Micaela K. Cendali, Francesca Ooyama, Gabrielle Gamboni, Fabia Morton, Holmes D’Alessandro, Angelo Front Physiol Physiology Background: Pyruvate kinase deficiency (PKD) is the most frequent congenital enzymatic defect of glycolysis, and one of the most common causes of hereditary non spherocytic hemolytic anemia. Therapeutic interventions are limited, in part because of the incomplete understanding of the molecular mechanisms that compensate for the metabolic defect. Methods: Mass spectrometry-based metabolomics analyses were performed on red blood cells (RBCs) from healthy controls (n=10) and PKD patients (n=5). Results: In PKD patients, decreases in late glycolysis were accompanied by accumulation of pentose phosphate pathway (PPP) metabolites, as a function of oxidant stress to purines (increased breakdown and deamination). Markers of oxidant stress included increased levels of sulfur-containing compounds (methionine and taurine), polyamines (spermidine and spermine). Markers of hypoxia such as succinate, sphingosine 1-phosphate (S1P), and hypoxanthine were all elevated in PKD subjects. Membrane lipid oxidation and remodeling was observed in RBCs from PKD patients, as determined by increases in the levels of free (poly-/highly-unsaturated) fatty acids and acyl-carnitines. Conclusion: In conclusion, in the present study, we provide the first overview of RBC metabolism in patients with PKD. Though limited in scope, the study addresses the need for basic science to investigate pathologies targeting underrepresented minorities (Amish population in this study), with the ultimate goal to target treatments to health disparities. Frontiers Media S.A. 2021-10-21 /pmc/articles/PMC8567077/ /pubmed/34744776 http://dx.doi.org/10.3389/fphys.2021.735543 Text en Copyright © 2021 Roy, Cendali, Ooyama, Gamboni, Morton and D’Alessandro. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Roy, Micaela K. Cendali, Francesca Ooyama, Gabrielle Gamboni, Fabia Morton, Holmes D’Alessandro, Angelo Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients |
title | Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients |
title_full | Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients |
title_fullStr | Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients |
title_full_unstemmed | Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients |
title_short | Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients |
title_sort | red blood cell metabolism in pyruvate kinase deficient patients |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567077/ https://www.ncbi.nlm.nih.gov/pubmed/34744776 http://dx.doi.org/10.3389/fphys.2021.735543 |
work_keys_str_mv | AT roymicaelak redbloodcellmetabolisminpyruvatekinasedeficientpatients AT cendalifrancesca redbloodcellmetabolisminpyruvatekinasedeficientpatients AT ooyamagabrielle redbloodcellmetabolisminpyruvatekinasedeficientpatients AT gambonifabia redbloodcellmetabolisminpyruvatekinasedeficientpatients AT mortonholmes redbloodcellmetabolisminpyruvatekinasedeficientpatients AT dalessandroangelo redbloodcellmetabolisminpyruvatekinasedeficientpatients |